---
title: 'Gene Therapy in Transfusion-Dependent Non-β0/β0 Genotype β-Thalassemia: First
  Real-World Experience of Beti-cel'
date: '2024-10-17'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39418614/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20241018203119&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Gene addition and editing strategies for transfusion-dependent β-thalassemia
  have gained momentum as potentially curative treatment options, with studies showcasing
  their efficacy and safety. We report the first real-world application of betibeglogene
  autotemcel (beti-cel; ZYNTEGLO™) during its period of active license in Europe from
  January 2020 to March 2022 for patients aged ≥ 12 years without a β0/β0 genotype
  and without a human leukocyte antigen (HLA)-matched sibling donor, before ...
disable_comments: true
---
Gene addition and editing strategies for transfusion-dependent β-thalassemia have gained momentum as potentially curative treatment options, with studies showcasing their efficacy and safety. We report the first real-world application of betibeglogene autotemcel (beti-cel; ZYNTEGLO™) during its period of active license in Europe from January 2020 to March 2022 for patients aged ≥ 12 years without a β0/β0 genotype and without a human leukocyte antigen (HLA)-matched sibling donor, before ...